Trial Profile

Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Laromestrocel (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Proof of concept
Acronyms CLEAR MIND
Sponsors Longeveron

Most Recent Events

01 Dec 2025 According to Longeveron media release, data from the trial were presented at the 18th Clinical Trials on Alzheimers Disease Conference (CTAD 2025).
01 Dec 2025 Results presented in the Longeveron Media Release.
19 Nov 2025 According to Longeveron media release, data from the trial will be presented at the 18th Clinical Trials on Alzheimers Disease Conference (CTAD 2025) to be held December 1-4, 2025 in San Diego, CA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com